These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22058102)

  • 1. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
    Singh BN; Dedhiya MG; DiNunzio J; Chan P; Kupiec TC; Trissel LA; Laudano JB
    Am J Health Syst Pharm; 2011 Nov; 68(22):2163-9. PubMed ID: 22058102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
    Chan P; Bishop A; Kupiec TC; Trissel LA; Gole D; Jimidar IM; Vermeersch H
    Am J Health Syst Pharm; 2008 Aug; 65(16):1545-51. PubMed ID: 18693210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration.
    Housman ST; Tessier PR; Nicolau DP; Kuti JL
    Am J Health Syst Pharm; 2011 Dec; 68(23):2265-70. PubMed ID: 22095816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compatibility of doripenem with other drugs during simulated Y-site administration.
    Brammer MK; Chan P; Heatherly K; Trusley C; Kupiec TC; Trissel LA; Psathas PA; Gilmor T; Schaufelberger D
    Am J Health Syst Pharm; 2008 Jul; 65(13):1261-5. PubMed ID: 18574017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration.
    Thabit AK; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2017 Jan; 74(1):e47-e54. PubMed ID: 28007721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physical compatibility of tedizolid phosphate with selected i.v. drugs during simulated Y-site administration.
    Ghazi I; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2016 Nov; 73(21):1769-1776. PubMed ID: 27769972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
    Ruiz VH; Shen Y; Abouelhassan Y; Fouad A; Nicolau DP; Kuti JL
    Am J Health Syst Pharm; 2024 Jan; 81(1):e21-e29. PubMed ID: 37740370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration.
    So W; Kim L; Thabit AK; Nicolau DP; Kuti JL
    Am J Health Syst Pharm; 2017 Jan; 74(1):e55-e63. PubMed ID: 28007722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
    Trissel LA; Williams KY; Gilbert DL
    J Am Pharm Assoc (Wash); 2000; 40(4):515-9. PubMed ID: 10932461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
    Lu J; Liu Q; Kupiec TC; Vail H; Lynch LR; Fam DS; Vu NT
    Int J Pharm Compd; 2021; 25(1):52-61. PubMed ID: 33503010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
    Trissel LA; Saenz CA; Ogundele AB; Ingram DS
    Am J Health Syst Pharm; 2004 Nov; 61(21):2289-93. PubMed ID: 15552637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection.
    Allen LV; Stiles ML; Prince SJ; Sylvestri MF
    Am J Health Syst Pharm; 1995 Nov; 52(21):2427-33. PubMed ID: 8564608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
    Trissel LA; Martinez JF; Simmons M
    J Am Pharm Assoc (Wash); 1999; 39(2):141-5. PubMed ID: 10079649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
    Avery LM; Chen IH; Reyes S; Nicolau DP; Kuti JL
    Clin Ther; 2019 Oct; 41(10):2162-2170. PubMed ID: 31506218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compatibility screening of bivalirudin during simulated y-site administration with other drugs.
    Trissel LA; Saenz CA
    Int J Pharm Compd; 2002; 6(4):311-5. PubMed ID: 23979308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
    Trissel LA; Martinez JF
    Am J Hosp Pharm; 1994 Mar; 51(5):672-8. PubMed ID: 8203388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
    Trissel LA; Gilbert DL; Martinez JF; Baker MB; Walter WV; Mirtallo JM
    JPEN J Parenter Enteral Nutr; 1999; 23(2):67-74. PubMed ID: 10081995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compatibility screening of hextend during simulated y-site administration with other drugs.
    Trissel LA; Williams KY; Baker MB
    Int J Pharm Compd; 2001; 5(1):69-72. PubMed ID: 23981801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
    Asempa TE; Avery LM; Kidd JM; Kuti JL; Nicolau DP
    Am J Health Syst Pharm; 2018 Jul; 75(14):1048-1056. PubMed ID: 29895521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compatibility screening of precedex during simulated y-site administration with other drugs.
    Trissel LA; Saenz CA; Ingram DS; Williams KY; Retzinger JP
    Int J Pharm Compd; 2002; 6(3):230-3. PubMed ID: 23979190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.